Skip to main content

Table 1 Baseline characteristics of patients in the trials included in the meta-analysis

From: Efficacy of mesenchymal stromal cells for the treatment of knee osteoarthritis: a meta-analysis of randomized controlled trials

Study Country Treatment regimen No. of patients Male/female Age(mean ± SD, year) Duration of follow-up (month) K-L criteria (2/3/4)
Emadedin [27] Iran 40 × 106 MSCs 19 12/7 51.7 ± 9.2 3,6 2/13/4
   Placebo 24 15/9 54.7 ± 5.3 3,6 1/20/3
Lamo-Espinosa [28] Spain 10 × 106 MSCs 10 4/6 65.9(59.5, 70.6) 6,12 1/2/7
   100 × 106 MSCs 10 8/2 57.8(55.0, 60.8) 6,12 3/3/4
   HA 10 7/3 60.3(55.1, 61.1) 6,12 4/2/4
Gupta [29] India 25 × 106 MSCs 15 NR 40–70 3,6,12 NR
   50 × 106 MSCs 15 NR 40–70 3,6,12 NR
   75 × 106 MSCs 15 NR 40–70 3,6,12 NR
   150 × 106 MSCs 15 NR 40–70 3,6,12 NR
   Placebo 15 NR 40–70 3,6,12 NR
Vega [30] Spain 40 × 106 MSCs 15 7/8 57 ± 9 12 NR
   HA 15 6/9 57 ± 9 12 NR
Varma [31] India MSCs 25 NR 48.2 ± 5.13 3,6 NR
   Arthroscopic debridement 25 NR 50.67 ± 5.38 3,6 NR
Saw [32] USA MSCs+HA 25 10/15 38 ± 7.33 6,12,18 NR
   HA 25 8/17 42 ± 5.91 6,12,18 NR
Vangsness [33] USA 50 × 106 MSCs 18 13/5 46 6,12,24 NR
   150 × 106 MSCs 18 13/5 46 6,12,24 NR
   HA 19 13/6 46 6,12,24 NR
Wong [34] Singapore MSCs+ high tibial osteotomy 28 15/13 53(36–54) 6,12,18,24 NR
   High tibial osteotomy 28 14/14 49(24–54) 6,12,18,24 NR
Ha [35] China 5 × 106 MSCs 44 14/30 55.6 ± 3.6 3,6,12 10/14/20
   HA 43 12/31 57 ± 3.2 3,6,12 11/11/21
  1. Abbreviation: SD standard deviation, K-L Kellgren-Lawrence, MSCs mesenchymal stem cells, NR not reported